Biomedical subjects

G L Burgess

Publications and source records attributed to G L Burgess.

5 recordsLinked to original sources

PubMed1999

Respirator leakage in the pharmaceutical industry of northwest England.

Field qualitative fit tests were conducted at 10 separate companies in the Northwest of England to determine the proportion of leaking respirators in a cross-section of pharmaceutical manufacturing industries. The 3 M FT-10 Qualitative Fit Test Apparatus was used to test a total of 211 half-face particulate respirator wearers. Participants wore their own respirators and were asked to don them as they would normally. In all cases, no specific intervention had occurred prior to testing. Results indicated a failure rate of 69% (of the 211 subjects tested, 145 respirators were leaking). Successful results were not associated with the frequency of use (p = 0.71) or years of experience wearing respirators (p = 0.59). Similarly, successful results were not associated with respirator training in the current job (p = 0.38) or training in previous jobs (p = 0.49). Leakage was not consistent across the 10 companies, with two companies exhibiting a 100% failure rate while another company had 26 successful tests in 50 wearers (52% pass rate). Only 35 of the 211 participants performed a negative pressure test. Of these, 80% successfully passed the test, which was significantly greater than the 22% pass rate among those who had not performed the pressure test (p < 0.001).

Drug Industry↗

PubMed1998

Development of an exposure matrix for respirable crystalline silica in the British pottery industry.

Processes associated with occupational exposure to respirable crystalline silica in the British pottery industry were investigated to develop estimates of worker exposures from 1930 to 1995. Information was derived from more than 1300 air samples, published literature and unpublished reports of dust control innovations and process changes. A matrix was developed specifically to support a mortality study of 5115 pottery workers in North Staffordshire, UK. Matrix values range from 2 micrograms/m3 for pottery support activities performed in the 1990s to 800 micrograms/m3 for firing activities in the 1930s. Although exposure estimates within decade varied, median concentrations for all process categories displayed an overall trend towards progressive reduction in exposure during the 65 year span. Potential methods to validate the matrix as well as sources of error are discussed.

Ceramics↗

PubMed1998

Crystalline silica and risk of lung cancer in the potteries.

OBJECTIVE: To evaluate crystalline silica as a human carcinogen. METHODS: A cohort of 5115 men, born 1916-45 and employed in the pottery, refractory, and sandstone industries of Stoke-on-Trent was identified from occupations subject to health surveillance by the local Silicosis Medical Board (now the Department of Social Security). Detailed occupational and smoking histories, and records of small parenchymal opacities on periodic radiographs were extracted from medical records. An exposure matrix was derived from some 1400 personal or static dust samples and tested against the presence of small parenchymal opacities in a subcohort of 1080 men employed for at least 10 years, who had started working in the industry before 1960. RESULTS: Standardised mortality ratios (SMRs) calculated against mortalities for Stoke-on-Trent, with 95% confidence intervals (95% CIs), were raised for all causes (1.15 (1.05 to 1.26)), lung cancer (1.28 (0.99 to 1.62)) and non-malignant respiratory disease (2.04 (1.55 to 2.65)). Average concentration and duration of exposure to silica were, taken together, significantly related to the presence of small opacities (> or = 1/0). In a nested case-referent analysis of 52 cases of lung cancer and 197 matched referents, conditional logistic regression gave a significantly increased odds ratio (OR) for average silica concentration (micrograms/m3.100), after adjustment for smoking, of 1.66 (1.14 to 2.41) but not for duration of exposure nor, in consequence, for cumulative exposure. CONCLUSION: The association between risk of lung cancer and quantitative estimates of silica exposure supports the SMR analysis and implies that crystalline silica may well be a human carcinogen.

Aged↗

PubMed1997

Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin.

INTRODUCTION: During the 1970s, scientists suggested that the growing use of chlorofluorocarbons (CFCs) was contributing to depletion of the stratospheric ozone layer with potentially harmful results. A committee on the ozone layer organized the preparation of the Montreal Protocol. This protocol mandated the cessation of production and use of CFCs by January 1, 1996. The primary exemption to this ban is for the use of CFCs as propellants in metered dose inhalers (MDIs) for the treatment of asthma. Suitable replacement hydrofluoroalkane (HFA) propellants, such as HFA-134a, for use in MDIs have been identified. Albuterol, a selective beta-adrenergic agonist, currently widely available for inhalation asthma therapy, has been reformulated in HFA-134a (Proventil HFA). OBJECTIVE; To compare the efficacy of Proventil HFA to Ventolin, Proventil, and placebo (HFA-134a) MDI in protecting asthmatic patients from exercise-induced bronchoconstriction. METHODS: This was a randomized, single-blind, placebo-controlled, 4-period crossover study of asthmatic patients with documented exercise-induced broncho-constriction. Twenty patients self administered two puffs of either Proventil HFA, Ventolin, Proventil or placebo, from an MDI, 30 minutes prior to performing a standardized exercise challenge at the study site. Spirometry was performed predose and 5, 10, 15, 30, 45, 60, 75, and 90 minutes after completion of the exercise challenge. Heart rate and blood pressure were measured just prior to spirometry and a 12-lead ECG was performed 15 minutes after completion of the exercise challenge for measurement of the QT corrected interval. RESULTS: The primary efficacy variable was the smallest percent change from the predose FEV1 following exercise. The smallest percent change from predose FEV1 for Proventil HFA was 2.0 +/- 9.9 SD, similar to the 2.0 +/- 11.4 SD for Ventolin, and the 3.6 +/- 10.2 SD for Proventil. The smallest percent change from predose FEV1 for each of the active treatments was significantly different from placebo, -23.7 +/- 14.5. Twelve of the patients had a > or = 20% fall in FEV1 post-exercise with placebo pretreatment, but only 1, 1, and 0 had > or = 20% FEV1 falls after treatment with Proventil HFA, Ventolin, and Proventil respectively. Changes in heart rate, blood pressure and QT corrected interval were similar for the three active treatments following exercise. CONCLUSIONS: Proventil HFA provides protection against exercise-induced bronchoconstriction comparable to Ventolin and Proventil and protection superior to placebo. Proventil HFA has a safety profile similar to Ventolin when used to prevent exercise-induced bronchoconstriction.

Adolescent↗

PubMedDate not supplied

The philosophy behind setting your group's fees.

According to author Gregory Burgess, fee adjustments are an invitable part of practice management; therefore, increasing the odds that a payment will be allowed when increased is a necessity. His article explains how to use insurance reimbursement data to do just that.

Actuarial Analysis↗